Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ATMI, a provider of development materials for life sciences industry, has unveiled a new technology for large-scale, cell-based manufacturing using its Integrity Xpansion Bioreactor Systems.
Subscribe to our email newsletter
The new range of bioreactors has been developed for fragile adherent cell culture applications on a large scale.
The Integrity bioreactors support safe and cost-efficient large-scale (large volume) production of traditional two-dimensional (2-D) cell cultures as it has cell culture parameter controls.
The 2-D multiplate design of the Xpansion bioreactors offers the same cell environment as standard multitray technology, besides providing the benefit of a closed system for increased protection from potential contamination.
ATMI LifeSciences cell culture technologies global director Jose Castillo said the Xpansion bioreactors represent a solution for process industrialization for cell therapies.
"Both patient safety and GMP compliance have been factored into the system’s design, as has operational simplicity," Castillo added.